ImmunoGen Inc (NASDAQ: IMGN) has reported E.P.S. of $0.10 for its third fiscal quarter (ending September 30) versus $-0.31 for the same period a year ago. Relative to the consensus estimate of $0.04, this was a premium of $0.06. For the latest four quarters through September 30, E.P.S. were $-0.28 versus $-0.82 for the same period a year ago.
Recent Price Action
On 11/2/23, ImmunoGen Inc (NASDAQ: IMGN) stock enjoyed a large increase of 3.7%, closing at $15.50. The stock has risen 13.2% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, IMGN is expected to be a major Value Builder.
ImmunoGen has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. ImmunoGen has a very low Appreciation Score of 5 but a very high Power Rating of 98, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment